Of course, with these shifts comes associated regulatory implications. The FDA and EMA have been introducing best practices and guidance around using the latest technology — and will continue to do so in the coming months.
Digital transformation is no longer optional in the life sciences sector, and agility is key to your organization’s ability to capitalize on the latest shifts and remain competitive.
Join us for a deep-dive discussion between Gilad Langer, Industry Practice Lead at Tulip, and Michelle Vuolo, Quality Practice Lead at Tulip, on the current state of frontline operations — and what to expect in 2024.
In this webinar, they’ll:
Analizar las previsiones que habíamos hecho para 2023 y si se han cumplido o no.
Outline some of the current life sciences industry shifts and frontline operations challenges
Destacamos nuestras previsiones para 2024 y te ofrecemos consejos sobre cómo adaptar tu estrategia en consecuencia.
Con la participación de:
-
Michelle Vuolo
Responsable de Calidad, Tulip
-
Gilad Langer
Responsable de prácticas del sector, Tulip